|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
08622 HUAKANG BIOMED
Nominal 
0.205 0.000 (0.000%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 11,918 | 3.951% | 24,629 | 25,330 | 26,127 | 21,967 |
| Cost of Sales | (3,929) | 0.204% | (8,536) | (8,416) | (9,671) | (7,249) |
| Gross Profit | 7,989 | 5.899% | 16,093 | 16,914 | 16,456 | 14,718 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | (2,556) | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | 7 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | (40) | |
| Profit / (Loss) before Taxation | (1,779) | 27.162% | (5,782) | (3,007) | (3,903) | (11,372) | |
| Taxation | 0 | -- | 0 | (68) | (317) | (255) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (1,779) | 22.268% | (5,782) | (3,075) | (4,220) | (11,627) | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (129) | -12.245% | (351) | (354) | (77) | (111) |
| Depreciation & Amortisation | 1,736 | 0.405% | 3,179 | 3,140 | 2,949 | 3,194 |
| Directors' Emoluments | 1,025 | 6.549% | 2,743 | 2,991 | 2,453 | 3,844 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -0.380 | 8.571% | -1.390 | -0.760 | -1.060 | -2.910 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.000 | 0.003 | (0.006) | (0.010) |
| NBV per share ($) | 0.113 | -- | 0.122 | 0.136 | 0.144 | 0.155 |
| Remarks: | Real time quote last updated: 11/11/2024 08:24 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -1,779,000 |
| %Change | 22.268% |
| EPS / (LPS) | RMB -0.004 |
| NBV Per Share (¥) | RMB 0.113 |